biomedical industry
It is one of the key pioneering industry clusters in Nanjing.
It is also the construction of Nanjing as an industrial powerhouse,
Main thrusts for the development of new qualitative productivity
Recently, the municipal party committee network information office to organize and carry out the "discovery of Nanjing" new media line and into the biomedical industry network theme interviews, the central and provincial key news network media, financial new media composed of a total of more than 20 people, the interview delegation.Entering Nanjing Biomedical Valley, visiting R&D laboratories, dialoguing with enterprise technical team, field researching new technologies, new thinking and new achievements of Nanjing biomedical industry.
Nanjing is "out of the loop" again.
Check out the media spotlight.
👇🏻
China Jiangsu Network
How can Nanjing's biomedical industry break through to the 100 billion track?(Original link: https://finance.jschina.com.cn/202503/t20250306_s67c9487de4b05777c1786f14.shtml)
Surfing news six dynasties ancient capital of Nanjing how to "high jump", open the biomedical industry new pattern(Original link: https://m.thepaper.cn/newsDetail_forward_30329967)
NiuKa Video
Nanjing Biomedical Valley: The Wave of Innovation, Biomedical Industry's "Cocoon" Road(Original link: http://m2.nbs.cn/article/917805.html?id=917805&mid=1)
China Business News ServiceThe Nanjing Treasure Valley is full of experts.(Click on the jump link)
Creators Commune
Follow the media's pen and camera
Let's explore together.
Nanjing Biomedical Industry
The Story Behind the Story
👇
Deciphering the "code of life".Pilot Gene Technology
○Genes affect human beings throughout life. In the process of exploring genes, the help of gene testing instruments is indispensable. However, gene sequencers involve chips, information algorithms and other science and technology, with high technical barriers, large investment in research, and a long research and development cycle, and only a handful of companies around the world are currently able to realize mass production.
Since its establishment in 2012, Zenmax Bio has been committed to the research and development of domestic gene sequencers.After several years of technological research, we have owned the "SURFSeq" sequencing technology system with independent intellectual property rights, and have realized the independent control of the whole platform of "Instrument, Reagent, Chip, and Software". "SURFSeq is one of the few sequencing system manufacturers in the world that possesses the upstream core technology of gene sequencing and the ability of commercialization and delivery.
○"The relationship between gene sequencers and testing chips is similar to that of printers and ink cartridges, in which the chips, as high-tech consumables, incorporate knowledge from a variety of disciplines such as physics, chemistry and biology." Zhou Zhiliang, general manager of Nanjing Zenmax Bio, used the analogy of a printer and an ink cartridge to vividly introduce the principles and functions of gene sequencers. "We started to lay out the overseas market three years ago, and now the revenue of the overseas market is equal to that of the domestic. While expanding the market, we are constantly updating our products, and our multi-gradient product array can fully meet the sequencing application needs of research institutions, medical institutions and industrial users, empowering cutting-edge scientific research exploration and precision medicine."
Meanwhile, in the Biomedical Valley of Nanjing's Jiangbei New District, another pharmaceutical company has also emerged as a breakthrough in innovation.
Early detection, early diagnosis and early treatment" is currently recognized as the most effective anti-cancer strategy. The "Shiho Hawkeye" pan-cancer early screening product independently developed by Shiho Genetics can screen nine types of cancers, including lung, liver, stomach, prostate, breast, esophageal, endometrial, and pancreatic cancers, and locate the diseased organs in one go, with only one tube of blood.It has become one of the only 4 multi-cancer early screening products in the world to receive FDA's breakthrough certification, and its technology has reached the world's leading level.
○ In October 2023, Shiho One NGS Large Panel Kit, independently developed by Shiho Genetics, passed the approval of innovative medical devices by the State Drug Administration for marketing.Became the first and currently the only tumor NGS Large Panel (gene combination) kit in China.
From a local unicorn to a global technology breaker, Shiho Genetics has been deeply engaged in tumor precision testing for more than 10 years, and with millions of samples tested and a high ratio of R&D investment, it has been ranked as the top of the market share of tumor NGS testing in China. As an oncology medical enterprise cultivated and grown locally in Nanjing Jiangbei New District, Shiho Genetics has built industry-academia research bases with many universities and research institutes in Nanjing, and recruited talents from multiple disciplines, such as biology and AI, and at the same time, it has also cooperated with Nanjing Medical University and Southeast University to cultivate talents together.
Innovation breakthrough, from local to global competition
○ In Nanjing, innovative drugs are accelerating overseas.
○ At the end of last year, a Hong Kong patient was treated with an innovative drug from Reindeer Biologicals, an enterprise in Jiangbei New Area, the CAR-T cell product Igibi Orensei Injection (FUCASO). In providing treatment for the first Hong Kong patient, Nanjing Customs and Jiangbei New Area jointly supervised the mechanism to open the bottleneck of cross-border logistics, realizing that the transportation of blood samples from Hong Kong patients to Nanjing and the start of preparation were completed within 48 hours.
○ Unlike traditional drugs and treatments, this therapy is China's first self-developed and full-process independent production, and customized for patients. Specifically, it treats hematologic malignancies by collecting T-cells from the patient's blood, transforming the T-cells in the laboratory, and then infusing the transformed CAR-T cells back into the body.
○ Lin Menghan, secretary of the board of directors of Reindeer Biologicals, introduced that the innovative drug has benefited hundreds of patients since it was approved for marketing by the State Drug Administration in June 2023 until now.Produced in Nanjing and supplied overseas, Reindeer Biologics cooperates with many organizations to promote cell therapy drugs "going overseas" and actively explores the mode of overseas patient attraction. The exploration of this innovative model, as well as excellent clinical results, has attracted more than 20 overseas patients from Europe, Africa, Southeast Asia and other places to receive treatment in China.
○ "Devices are becoming smaller and smaller and more and more powerful." Founded in Nanjing in 2000, Nanwei Medical is mainly engaged in the research, development, production and sales of minimally invasive medical devices and consumables. As a pioneer of domestic substitution, its "Harmony Clamp" launched in 2015 realized 360-degree precision clamping with a slide slot structure, and the price is only 1/8 of imported similar products, ending the monopoly of foreign brands, and the annual output value of a single product reaches hundreds of millions of yuan. Since then, the innovative product "disposable choledochoscope" is able to penetrate into the biliary tract, realize high-definition biliary imaging, and carry out super minimally invasive endoscopic diagnosis and treatment.
○ According to Li Changqing, Executive President of Nanwei Medical, the company has served more than 6,000 hospitals nationwide, covering more than 55% tertiary hospitals, and has become a leading company in the domestic minimally invasive medical device industry. Overseas market, is also the target of Nanwei Medical's strength. "Today, the company's products and services can reach more than 90 countries and regions, and in the future the company will continue to lead with innovation."
From single-point breakthrough to whole-chain synergy
Steady rise of ecological clusters
○ Nanjing is located in the Yangtze River Delta, with well-developed transportation and strong radiation-driven effect, as well as a concentration of universities and colleges with abundant scientific, educational and clinical resources. From the research and development of gene sequencers to the use of genetic testing in medical treatment, and from innovative drugs going out to the world, Nanjing Biomedical Valley provides a complete upstream and downstream industrial chain for the biomedical industry, enabling enterprises to efficiently share resources and technologies and promote the research, development and production of innovative drugs.
At the same time, focusing on the needs of the biomedical industry for "crowdsourcing+incubation+acceleration+industrialization".Nanjing Biomedical Valley provides full-featured carrier space, full life-cycle services, and full-factor innovation ecological environment, and has now built nearly 1.9 million square meters of innovation and entrepreneurship carriers.
○ Relying on Nanjing's rich university resources, Nanjing Biomedical Valley has attracted a large number of high-level talents.Up to now, the park has introduced 52 experts under the National Talent Project Program, 99 talents under the Jiangsu Province "Shuangchuang Program", and 15 top experts in science and technology in Nanjing. In addition, the park also has 5 national postdoctoral workstations and 8 provincial postdoctoral innovation and practice bases, providing strong support for the cultivation and retention of talents.
Through policy tools such as the "fast track for urgently needed clinical devices" and the "Biomedical Industry Fund", Nanjing has helped innovations realize a seamless transition from "laboratory - operating room - production line" to "tropical rainforest effect" for industrial development. ○ Through policy tools such as the "Fast Track for Clinically Needed Devices" and the "Biomedical Industry Fund", Nanjing has helped innovations realize the "laboratory-operating room" and "production line" seamless connection, which has given rise to the "rainforest effect" of industrial development.
In order to implement "precise drip irrigation" services for biomedical enterprises, Nanjing has set up a 2 billion yuan biomedical industry mother fund to provide key support in the fields of innovative drugs, medical devices and biotechnology for research and development projects with positive clinical phase III data or those about to enter into commercialization, high-quality talents with technological transformation value, and mergers and acquisitions and restructuring of leading enterprises. Give key support to promote the virtuous cycle of "science and technology - industry - finance".
Reconstructing the industrial pattern with "global vision + local wisdom", "two-way empowerment" not only brings the acceleration of technology iteration, but also promotes Nanjing to move from "Made in China" to "Global Innovation Center". The "two-way empowerment" not only accelerates the iteration of technology, but also promotes Nanjing's leap from "Made in China" to "the source of global innovation".At present, the scale of Nanjing's biomedical industry has exceeded 200 billion yuan, and the comprehensive competitiveness of Nanjing Biomedical Valley ranks eighth in the country.It is a high-quality development cluster demonstration area in Jiangsu Province, and has successfully landed the National University Regional Technology Transfer and Transformation Biomedical Sub-Center, which is moving towards the goal of 100 billion life and health industry clusters.
